Search for a trial

Phase II trial of the combination of gemcitabine and 131I-MIBG therapy in paediatric patients with relapsed or progressive neuroblastoma

To evaluate the efficacy and toxicity of gemcitabine in combination wth 131I-MIBG in pediatric patients with relapsed or progressive neuroblastoma.

Individualizing Pazopanib therapy by exploRing the role of Early metabolic responsE and drug exposure as a preDICTor for treatment outcome in patients with STS

Primary Objectives:- To evaluate whether early metabolic response is correlated to clinical benefit (defined as PFS).- To evaluate the effect of age (>= 70 years) on pazopanib pharmacokinetics (AUC0-24hr).Secondary Objectives:- To evaluate…

Gastrointestinal stromal tumors: assessment of mutations in tumors and in circulating tumor DNA and measurement of TKI plasma exposure to optimize treatment

Primary objectives:• To assess whether secondary GIST mutations can be found in circulating tumor DNA of patients with progressive disease on TKI treatment (according to RECIST 1.1 on computer tomography), whereas they are NOT present in the…

A phase II study of orally administered BEZ235 monotherapy in patients with metastatic or unresectable malignant PEComa

Efficacy of BEZ235 on objective response rate according to RECIST 1.1

A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered
as a Single Agent Every 2 Weeks in Patients With Previously-
Treated, Advanced or Metastatic Soft Tissue and Ewing's
Sarcoma/PNET

The primary objective of this study is to determine the progression-free survival (PFS) rate assessed 12 weeks after the initiation of IMC-A12 monotherapy, administered every 2 weeks to patients with previously-treated, advanced or metastatic soft…

Antiviral therapy (cidofovir, an acyclic nucleoside phosphate) in combination with radiotherapy in HPV-positive tumours of the oropharynx: a phase 1 study.

Primary objective ·To define the maximum tolerated dose (MTD) of cidofovir in combination with standard dose of radiotherapy in Human Papilloma Virus-positive head and neck carcinomas.Secondary Objectives·To explore p53-related gene activity in…

Randomized phase II trial of cabazitaxel or prolonged infusional ifosfamide in metastatic or inoperable locally advanced dedifferentiated liposarcoma

The main objective is to determine whether cabazitaxel or prolonged infusional ifosfamide demonstrate sufficient antitumor activity (as measured by progression free survival at 12 weeks) in pre-treated patients with metastatic or inoperable locally…

"The Shrink Study: shrink factor of resected tumour mucosa in patients with oral squamous cell carcinoma"

Investigate whether different resection modalities such as MO or TL cause a different amount of shrinkage in the mucosal margins of resected OSCCs.

A Phase 4, Multicenter Study to Evaluate Discontinuation and Re-Treatment in Subjects with Tenosynovial Giant Cell Tumor (TGCT) Previously Treated with Pexidartinib

Main objective: Proportion of subjects who remain treatment-free.Secondary objectives: - Change from Baseline in Patient Reported Outcomes (PROs) (PROMISPF, EQ-5D-5L)- Safety: Total number of subjects in the safety analysis set with any AEcollected…

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO) (study 208467)

This study has been transitioned to CTIS with ID 2024-513032-14-00 check the CTIS register for the current data. Primary:To evaluate the efficacy of NY-ESO-1-Specific (c259) T Cells, alone or in combination with other anti-cancer agents, in HLA-A*02…

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, alone or in combination with other agents, in Participants with Advanced Tumors (study 209012)

Primary:To assess the safety, tolerability and determine recommended phase 2 dose (RP2D) of NY-ESO-1 and LAGE-1a specific T cells, alone or in combination with other agents, in HLA-A*02-positive participants with NY-ESO-1 and/or LAGE-1a positive…

Assessment of the Safety and Performance of the AB1 Electrosurgical System for Bronchoscopic Microwave Ablation of Lung Tissue (AB1MALT)

The overall purpose of this study is to confirm the clinical safety and performance of the AB1 instrument in subjects undergoing bronchoscopic pulmonary nodule microwave ablation procedures performed using the AB1 electrosurgical system.

Cemiplimab treatment in patients with locally advanced and metastatic secondary angiosarcomas

Primary objective: 1) To evaluate the overall response rate (ORR) after 24 weeks of cemiplimab in secondary angiosarcomas, according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 or daylight photography as per WHO Offset Publication…

Magnetic Resonance imaging-guided high intensity focused ultrasound for patients with Desmoid-type fibromatosis

The aim of this study is to assess the efficacy of MR-HIFU as a treatment modality for desmoid-type fibromatosis (DTF).

Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety, pharmacokinetics,
pharmacodynamics, and preliminary efficacy of BNT141 as a monotherapy and in combination with other anti-cancer agents in
patients with CLDN18.2-positive solid tumors

To assess the safety and tolerability ofBNT141 at different dose levels.To identify the maximum tolerated dose (MTD) or maximally administered dose (MAD) /recommended Phase IIdose (RP2D) of BNT141 based on theoccurrence of dose-limiting toxicities(…

A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination with Gemcitabine in Adult and Pediatric Subjects with Relapsed or Refractory Osteosarcoma.

Primary:Phase 1: • To investigate the safety and tolerability, including identification of the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ZN-c3 in combination with gemcitabinePhase 2: • To evaluate the clinical activity of…

Neoadjuvant trial on the efficacy of propranolol monotherapy in angiosarcoma.

The primary objective is to determine the clinical response of propranolol monotherapy in patients with angiosarcoma. The secondary endpoint is to assess the pathologic response of propranolol monotherapy in patients with angiosarcoma.

A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects
with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Dose Escalation: * To determine the MTD or the RP2D of tazemetostat when administered as an oral suspension BID in pediatric subjects with relapsed/refractory rhabdoid tumors, INI1-negative tumors or synovial sarcoma.* To evaluate the preliminary…

Dose Reduction of preoperative radiotherapy in myxoid liposarcoma

To study the feasibility of reducing the dose of preoperative radiotherapy in MLS from 50Gy to 36Gy while maintaining comparable clinicopathological responses.

The influence of the new HME Energy on physical activity and patient satisfaction in laryngectomized patients

-To describe the differences in the parameters of physical exertion during physical activity with two different HMEs in both a lab and daily life setting-To asses patients* satisfaction with both types of HMEs